Who are Fulvestrant combined with Pyrotinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fulvestrant-combined-with-pyrotinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fulvestrant combined with Pyrotinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fulvestrant combined with Pyrotinib (Fulvestrant combined with Pyrotinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor degrader (SERD) combined with HER tyrosine kinase inhibitor. Area: Oncology.

phase 3 Selective estrogen receptor degrader (SERD) combined with HER tyrosine kinase inhibitor Estrogen receptor (ER) and HER1/HER2/HER4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fulvestrant combined with Pyrotinib (Fulvestrant combined with Pyrotinib) — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Fulvestrant blocks estrogen receptor signaling while pyrotinib inhibits HER2 tyrosine kinase, together targeting hormone receptor-positive and HER2-positive breast cancer through dual pathway inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fulvestrant combined with Pyrotinib TARGET	Fulvestrant combined with Pyrotinib	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Selective estrogen receptor degrader (SERD) combined with HER tyrosine kinase inhibitor	Estrogen receptor (ER) and HER1/HER2/HER4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor degrader (SERD) combined with HER tyrosine kinase inhibitor class)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fulvestrant combined with Pyrotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/fulvestrant-combined-with-pyrotinib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab